Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver

Figures & data

Table 1 Currently Recruiting Clinical Trials for Fibrolamellar Carcinoma

Trial Title	Phase	Trial Drugs	Estimated Enrollment Patient No.	Primary Objective
DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma (NCT04248569)	1	1. DNAJB1-PRKACA peptide vaccine 2. Nivolumab 3. Ipilimumab	12	Safety and interferon-producing DNAJB1-PRKACA-specific T-cell response at 10 weeks
Nivolumab, 5-Fluorouracil and Interferon-α2b for the treatment of unresectable fibrolamellar carcinoma (NCT04380545)	1/2	1. Fluorouracil 2. Nivolumab 3. Recombinant Interferon Alpha 2b-like protein	15	Safety
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) (NCT03017326)	3	1. Carboplatin 2. Cisplatin 3. Doxorubicin 4. Etoposide 5. Flourouracil 6. Gemcitabine 7. Irinotecan 8. Oxaliplatin 9. Sorafenib 10. Vincristine Sulfate	450	Event-free survival
Fc-engineering anti-CTLA-4 monoclonal antibody in advanced cancer (NCT03860272)	1	1. Botensilimab 2. Balstilimab	195	Incidence of treatment-emergent adverse events, dose-limited toxicity of botensilimab, recommended Phase 2 dose of botensilimab
Safety and efficacy of cyclophosphamide, sorafenib, bevacizumab, and atezolizumab in pediatric solid tumor patients (NCT05468359)	1/2	Atezolizumab Sorafenib Bevacizumab Cyclophosphamide	64	Recommended phase 2 dose, pharmacokinetics of sorafenib, response rate, intratumoral T cell infiltration of CD8+CD45RO+ cells
Checkpoint inhibition in pediatric hepatocellular carcinoma (NCT04134559)	2	Pembrolizumab	18	Immune-related best overall response
A study of DT2216 in Relapsed/Refractory Malignancies (NCT04886622)	1	DT2216	24	Safety and dose limiting toxicity

Note: Data gathered from clinicaltrials.gov.